ADC Therapeutics SA expected to post a loss of 56 cents a share - Earnings Preview

ADC Therapeutics SA

03/05/2024 13:39

* ADC Therapeutics SA  ADCT.N   ADCT.K  is expected to show
a fall
in quarterly revenue when it reports  results on May 6 for the
period ending March 31 2024
    * The Epalinges Vaud-based  company is expected to report a
4.7% decrease in revenue to $18.102 million from $18.99 million
a year ago, according to the mean estimate from 6 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for ADC Therapeutics SA is
for a
loss of 56 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 8.5%
in the last three months. ​
    * Wall Street's median 12-month price target for ADC
Therapeutics
SA is $10.00​, above​ its last closing price of $4.73. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.48       -0.50      -1.03     Missed  -104.8
 Sep. 30 2023  -0.65       -0.63      -0.58     Beat    8.5
 Jun. 30 2023  -0.35       -0.46      -0.58     Missed  -26.9​
 Mar. 31 2023  -0.76       -0.67      -0.74     Missed  -10.4
 ​​Dec.        -0.21       -0.29      -0.30     Missed  -4.6
 31 2022                                                
 Sep. 30 2022  -0.30       -0.35      -0.65     Missed  -84.2​
 Jun. 30 2022  -0.92                  -0.84             8.1
 Mar. 31 2022  -0.69       -0.70      -0.22     Beat    68.4
 This summary was machine generated May 3 at 12:39 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)